A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.

计划入组 70 人 · 首次发布于 2025 年 6 月 12 日

5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors

计划入组 20 人 · 首次发布于 2026 年 5 月 15 日

Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors

计划入组 40 人 · 首次发布于 2022 年 1 月 18 日

5T4-5T4-CD3

UCART-5T4

MVA.5T4 Vaccine

ANTIGEN LABORATORIES INC.

United States

Poseida Therapeutics

United States

Barinthus Biotherapeutics

ALG.APV-527 Bispecific Antibody Shows Promise in Phase 1 Solid Tumor Trial

Purple Biotech to Present Novel CAPTN-3 Tri-Specific Antibody Platform at EACR 2025

Aptevo's ALG.APV-527 Shows Promise in Solid Tumors with Favorable Safety Profile in Phase 1 Trial